Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Verdinexor

Verdinexor
Contact us for more batch information
Select Batch
Purity:99.93%
Resource Download

Verdinexor

Catalog No. T6123Cas No. 1392136-43-4
Verdinexor (KPT-335) (KPT-335), a specific XPO1/CRM1 inhibitor, are orally bioavailable.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$48In Stock
2 mg$68In Stock
5 mg$113In Stock
10 mg$197In Stock
25 mg$359In Stock
50 mg$597In Stock
100 mg$953In Stock
1 mL x 10 mM (in DMSO)$125In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Verdinexor"

Product Introduction

Bioactivity
Description
Verdinexor (KPT-335) (KPT-335), a specific XPO1/CRM1 inhibitor, are orally bioavailable.
In vitro
In a model of autosomal dominant polycystic kidney disease, intraperitoneal injection of Verdinexor (5 mg/kg) weakened cyst growth by inhibiting XPO1. Administering Verdinexor orally (25 mg/kg) twice daily reduced the incidence and mortality of lung disease associated with lethal influenza A virus type, primarily by decreasing the expression of pro-inflammatory cytokines in the lungs, which in turn reduced pulmonary viral titers, thereby exhibiting antiviral activity.
In vivo
In Jurkat,OCI-Ly3,OCI-Ly10,和CLBL1 cells,Verdinexor inhibited cell viability with IC50 of 0.3 nM, 2.1 nM, 41.8 nM, and 8.5 nM, respectively. In Primary Canine DLBCL Cells and CLBL1 expressed XPO1 and SINE, KPT-335 induces apoptosis. Verdinexorpotently inhibits a variety of influenza virus strains, including the H1N1 epidemic virus, the highly pathogenic H5N1 bird flu virus, and the recently emerging H7N9 strain.
Cell Research
Cell viability for lymphoid lines is determined by the MTS assay using CellTiter 96? AQueous One Solution Cell Proliferation Assay Kit. Briefly, for lymphoid cell lines, 5×104 cells (or 1×105 primary DLBCL cells) are cultured in 100 μL of complete medium in 96-well plates in the presence of SINE compounds. After 72 hours, 20 μL of MTS solution is added to each well and cells are incubated for another 4 hours before measuring absorbance at 490 nm using a Wallac Victor 1420 Multilabel Counter. The IC50 of SINE is calculated using Prism 6 software. For the non-lymphoid cell lines, 96 well plates are seeded in triplicate in 90 μL with 2500 cells/well of OSA16, 5000 cells/well of C2, and 2500 cells/well of 323610-3. Seeded plates are cultured overnight then treated the following day with 10 μL of KPT-214 in C10 media at concentrations of 0.0001, 0.01, 0.1, 1.0, and 10 μM. Plates are collected at 92 hours, centrifuged at 1300 rpm, and supernatant is removed by inverting plates on absorbent paper. Plates are then sealed and immediately placed at ?80°C for a minimum of 12 hours. Plates are then thawed and CyQUANT ?Cell Proliferation Assay is performed following the manufacturer's protocol. Briefly, 200 μL of the diluted working CyQUANT solution is added to each well and protected from light. Fluorescence is the measured using a SpectraMax M2 microplate reader at 480 nm excitation and 520 nm emission. Results are represented as percent of control, or plotted to calculate IC50 values at 92 hours.(Only for Reference)
AliasKPT-335
Chemical Properties
Molecular Weight442.32
FormulaC18H12F6N6O
Cas No.1392136-43-4
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 82 mg/mL (185.4 mM)
Ethanol: 9 mg/mL (20.3 mM)
Solution Preparation Table
DMSO/Ethanol
1mg5mg10mg50mg
1 mM2.2608 mL11.3040 mL22.6081 mL113.0403 mL
5 mM0.4522 mL2.2608 mL4.5216 mL22.6081 mL
10 mM0.2261 mL1.1304 mL2.2608 mL11.3040 mL
20 mM0.1130 mL0.5652 mL1.1304 mL5.6520 mL
DMSO
1mg5mg10mg50mg
50 mM0.0452 mL0.2261 mL0.4522 mL2.2608 mL
100 mM0.0226 mL0.1130 mL0.2261 mL1.1304 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg, each TargetMol | Animal experiments animal weighs 20 g, and the dosage volume is 100 μL. A total of TargetMol | Animal experiments 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL.
Mother liquor preparation method: 2 mg of drug dissolved in 50 μLDMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μLDMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μLTween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.

Keywords